Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Pasic

Showing results (31-40 of 91) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|February 26, 2026
Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemiaNihar Desai, Mohammed Althobaiti, Carol Chen, et al.
European Journal of Haematology|July 18, 2023
Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remissionTommy Alfaro Moya, Jonas Mattsson, Mats Remberger, et al.
Transplantation and Cellular Therapy|March 10, 2024
Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell TransplantationAyman Sayyed, Carol Chen, Armin Gerbitz, et al.
British Journal of Haematology|August 27, 2025
A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantationNihar Desai, Sergio Rodriguez-Rodriguez, Eshrak Al-Shaibani, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 6, 2021
Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant PatientsEshrak Al-Shaibani, Rhida Bautista, Jeffrey H Lipton, et al.
European Journal of Haematology|December 14, 2025
Eltrombopag in Treating Post-Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug TaperingRawan Al-Omari, Ram Vasudevan Nampoothiri, Ali Sakhdari, et al.
European Journal of Haematology|May 8, 2025
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap NeoplasmsNihar Desai, Sergio Rodriguez-Rodriguez, Carol Chen, et al.
European Journal of Haematology|December 14, 2021
Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donorsIgor Novitzky-Basso, Mats Remberger, Carol Chen, et al.
Transplantation and Cellular Therapy|August 1, 2022
Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant RecipientsMuneyoshi Kimura, Victor H Ferreira, Sagar Kothari, et al.
Annals of Hematology|February 23, 2023
Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experienceEshrak Al-Shaibani, Shiyi Chen, Carol Chen, et al.
Pageof 10

Showing results (31-40 of 91) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|February 26, 2026
Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemiaNihar Desai, Mohammed Althobaiti, Carol Chen, et al.
European Journal of Haematology|July 18, 2023
Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remissionTommy Alfaro Moya, Jonas Mattsson, Mats Remberger, et al.
Transplantation and Cellular Therapy|March 10, 2024
Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell TransplantationAyman Sayyed, Carol Chen, Armin Gerbitz, et al.
British Journal of Haematology|August 27, 2025
A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantationNihar Desai, Sergio Rodriguez-Rodriguez, Eshrak Al-Shaibani, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 6, 2021
Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant PatientsEshrak Al-Shaibani, Rhida Bautista, Jeffrey H Lipton, et al.
European Journal of Haematology|December 14, 2025
Eltrombopag in Treating Post-Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug TaperingRawan Al-Omari, Ram Vasudevan Nampoothiri, Ali Sakhdari, et al.
European Journal of Haematology|May 8, 2025
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap NeoplasmsNihar Desai, Sergio Rodriguez-Rodriguez, Carol Chen, et al.
European Journal of Haematology|December 14, 2021
Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donorsIgor Novitzky-Basso, Mats Remberger, Carol Chen, et al.
Transplantation and Cellular Therapy|August 1, 2022
Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant RecipientsMuneyoshi Kimura, Victor H Ferreira, Sagar Kothari, et al.
Annals of Hematology|February 23, 2023
Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experienceEshrak Al-Shaibani, Shiyi Chen, Carol Chen, et al.
Pageof 10